28th September, 2026

To,
**The Listing Compliance Department**
**BSE Limited**
**P. J. Towers, Dalal Street**
**Mumbai – 400001**
**Scrip Code: 524632**

To,
**The Listing Department**
**National Stock Exchange of India Limited**
**Exchange Plaza, C-1, Block G**
**Bandra Kurla Complex, Bandra (East)**
**Mumbai – 400051**
**Symbol: SHUKRAPHAR**

**Sub: Proceedings of 33rd Annual General Meeting of the Company held on September 28, 2026**

Dear Sir/Madam,

This is to inform you that the 33rd Annual General Meeting ("**AGM**") of Shukra Pharmaceuticals Limited was held on Monday, September 28, 2026, at 12:00 p.m. through video conferencing ("VC")/ other audio-visual means ("OAVM") which concluded at 12:24 p.m. (IST).

In this regard, please find enclosed proceedings of the 33rd AGM pursuant to Part A of Schedule III read with Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on record and oblige

Thanking you,

Yours Faithfully

**For Shukra Pharmaceuticals Limited**

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380051, st=GUJARAT, street=27,JAGANNATH PARK ,JIVRAJ PARK ROAD ,AHMEDABAD,OCTROI NAKA ,380051, l=AHMEDABAD, o=Personal, serialNumber=3ba36a23be6b9f1e2035fcd9797976bc421cc9df8e8485c129a31d99a204d3e4, pseudonym=5d8b198923c743009cfd88f8b0069402, 2.5.4.20=02731363f2560213d31d8d522de3c70d17f63b08215cc5628399fab337751d60, email=DAKSHESHSHAH9@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.09.28 14:18:51 +05'30'

**Dakshesh Shah**
**Managing Director**
**DIN: 00561666**

Shukra Pharmaceuticals Limited
REG. NO.: 019079

**Encl.: As Above**

**SUMMARY OF PROCEEDINGS OF 33RD ANNUAL GENERAL MEETING (AGM) OF THE MEMBERS OF SHUKRA PHARMACEUTICALS LIMITED HELD ON MONDAY, SEPTEMBER 28, 2026 AT 12:00 P.M. THROUGH VIDEO CONFERENCING, UNDER REGULATION 30 (2) & OTHER APPLICABLE REGULATIONS OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.**

The 33rd Annual General Meeting (the "AGM") of the Members of Shukra Pharmaceuticals Limited (the "Company") was held on Monday, September 28, 2026 at 12:00 P.M. (IST) through video conferencing ("VC")/ other audio-visual means ("OAVM"), in compliance with the applicable provisions of the Companies Act, 2013, the Ministry of Corporate Affairs ("MCA") circulars dated 25th September 25, 2023, 28th December, 2022, 5th May, 2022, 14th December, 2021 read with circulars dated 13th January, 2021, 5th May, 2020, 8th April, 2020 and 13th April, 2020 (collectively referred to as "MCA Circulars") and SEBI circulars dated 5th January, 2023 ,13th May, 2022 read with 15th January, 2021 and 12th May, 2020 (collectively referred to as "SEBI Circulars").

Parshva Texchem India Private Limited, a corporate shareholder and promoter of the Company has proposed and authorized name of Mr. Dhruvin Shah, Executive Director of the Company to act as Chairman for the Annual General Meeting.

Mr. Dhruvin Shah, Executive Director of the Company, chaired the meeting, and welcomed all the members present at the virtual annual general meeting and started the formal proceedings.

Mr. Dhruvin Shah has given speech of chairman of this 33rd Annual General Meeting of the Shukra Pharmaceuticals Limited with the permission of the board of directors.

The Company secretary confirmed that the requisite quorum was present in the meeting and called the meeting to order and further introduced the Directors and other panelists present at the meeting.

Mr Shivkant Dhakad, Company secretary of the Company informed the Members about the general instructions regarding participation in the meeting. The Company Secretary informed the Members that the meeting was being held through video conferencing in accordance with the circulars issued by the Ministry of Corporate Affairs ("MCA") and Securities and Exchange Board of India ("SEBI"). He further informed that the Company had taken all the requisite steps to enable the Members to attend and vote at the meeting in a seamless manner. He also informed that the Company has availed the services of National Securities Depository Limited ("NSDL") for conducting the meeting through Video Conferencing, for enabling participation of the Members at the AGM, remote e-voting and e-voting during the AGM.

It was further informed that since the meeting was being held virtually, the facility for appointment of proxies is not applicable. He further informed the Members that as per the provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has provided an option to the members for voting through electronic mode viz. remote e-voting which remained open from Friday, September 25, 2026 from 9:00 a.m. and ends on Sunday, September 27, 2026 to 05:00 pm. Members who had not casted their votes earlier were also allowed to cast their votes electronically at the meeting and 15 minutes after conclusion of the meeting using the electronic voting system provided by NSDL.

The Company secretary further informed the members that the Board of Directors had appointed Mrs. Rupal Patel, Practicing Company Secretaries as the Scrutinizer to scrutinize the remote e-voting process and voting through e-voting system at the AGM in a fair and transparent manner.

Thereafter, chairman delivered speech. After the speech, the Company secretary declared that the Notice of the 33rd AGM along with copy of Audited Financial Statements for the Financial Year ended on 31st March, 2026 together with the Auditor's and Director's Report thereon was e-mailed within the statutory period to all the shareholders whose e-mail addresses are registered with the Company or RTA of the Company or their Depository Participants as on Friday, August 28, 2026 and was also hosted on the website of the Company at www.shukrapharmaceuticals.com, BSE, NSE and NSDL. Accordingly, the Notice of 33rd AGM and Director's Report were taken as read.

He informed that the Audit Report on Financial Statements for the Financial Year ended on 31st March, 2026 does not contain any qualification, reservation or adverse remarks and hence was taken as read.

Thereafter, the following items of business as set out in the Notice convening the 33rd AGM were transacted:

| S.N. | Particulars | Type of Resolution |
|---|---|---|
| | **Ordinary Business** | |
| 1 | Consideration and Adoption of the Audited Financial Statements of the Company for the Financial Year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon | Ordinary Resolution |
| 2 | Approve and declare final dividend for the financial year 2025-26 | Ordinary Resolution |
| 3 | Re-appointment of Ms. Sanskruti Patel (DIN: 07108631) as a Director (Executive), who retires by rotation and being eligible, offers herself for re-appointment | Ordinary Resolution |
| 4 | Regularization of appointment of Additional Independent Director Mr. Dinesh Chauhan (DIN: 11456530), as an Additional Independent Director of the Company | Special Resolution |

None of the shareholders has raised any quires during the 33rd Annual General Meeting.

He also mentioned that the results of voting shall be announced within 48 hours of conclusion of meeting. The results of voting will be displayed on the website of the Company, NSDL and Stock Exchanges in due course.

The Chairman thanked the members for participating in the meeting. The meeting concluded at 12:24 p.m. (IST).

This is for your information and records.

Thanking you.
Yours faithfully,

**For Shukra Pharmaceuticals Limited**

DAKSHESH RAMESHCHANDRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380051, st=GUJARAT, street=27,JAGANNATH PARK ,JIVRAJ PARK ROAD ,AHMEDABAD,OCTROI NAKA ,380051, l=AHMEDABAD, o=Personal, serialNumber=3ba36a23be6b9f1e2035fcd9797976bc421cc9df8e8485c129a31d99a204d3e4, pseudonym=5d8b198923c743009cfd88f8b0069402, 2.5.4.20=02731363f2560213d31d8d522de3c70d17f63b08215cc5628399fab337751d60, email=DAKSHESHSHAH9@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.09.28 14:19:38 +05'30'

**Dakshesh Shah**
**Managing Director**
**DIN: 00561666**

Shukra Pharmaceuticals Limited
REG. NO.: 019079